Name: 4th Annual MarketsandMarkets Bioprocessing of Advanced Cellular Therapies Congress-VIRTUAL (Time Zone -GREENWHICH MEAN TIME (GMT))
Start: 2020-10-29
End: 2020-10-30

20+

Speakers

100+

Attendees

6+

Networking Hours

4+

Sessions

EVENT OVERVIEW

Devising the effective manufacturing and quality control methods of cell therapies

Regenerative therapies are proving its acceptance in potential of cell-based therapies for chronic disorders. Since our past three editions, our aim through this conference is to provide illustrative approach to recent developments in technologies of bioprocessing of cellular therapies, to process development and addressing qualitative and regulatory hurdles.

In the 4th edition of MarketsandMarkets Bioprocessing of Advanced Cellular Therapies Congress-VIRTUAL, we would be focusing on the manufacturing, process development, regulatory aspects of cell therapies and gene therapies. The special impact would be laid on, gene delivery based therapies, car-T cell-based immunotherapies, automated manufacturing, allogenic therapies, with the aspects of hurdles in supply chain management and regulatory affairs.

Click here to view the post show report for the 2nd Annual MarketsandMarkets Cell-Gene therapy Bioprocessing Online Conference

• Stem cell transplantation for cellular aspects
• Culture technology for cell & Gene therapy applications
• Ex-vivo cell and gene therapy manufacturing
• Autologous gene therapy delivery
• Conventional Car-T cell delivery
• Allogenic Car-T cell therapy application
• Quality control in manufacturing of cell therapy
• Supply chain management for cell therapy management
• Regulatory and reimbursement issues based on GMP guidelines

Vice Presidents
Directors
Managers
Heads
Leaders
Engineers
Scientists
Professors
Researchers
Project leaders

Cell Culture
Cell Therapy
Upstream Processing
Stem Cell therapy
Process Development
Bioprocessing
Downstream Processing
Quality Control
Bioengineering
Translational Sciences
Scale-up/out
Bioprocess development
Quality Control
Biotherapeutics
Cell Engineering
Regulatory affairs

CONFERENCE AGENDA

Registrations	08:00 - 08:50
Welcome address by MarketsandMarkets	08:50 - 08:55
Opening remarks by Chairperson Petter Bjorquist, CEO, Verigraft	08:55 - 09:00
Personalised organs that will revolutionise future medicine Petter Bjorquist, CEO, Verigraft	09:00 - 09:30
UPSTREAM PROCESSING OF CELL & GENE THERAPIES
Bioprocessing of cells and exosomes for regenerative medicine Ivan Wall, Professor of Regenerative Medicine, Cell & Gene Therapy Bioprocessing, Aston University	09:25 - 09:50
Automated Cell Culture Analysis – Process Development to GMP Roystein Bulman, European Applications Manager, Nova Biomedical	09:50 - 10:20
Development of Combinatorial Culture Technology for cell and gene therapy applications Marina Tarunina, Research Director, Plasticell Limited	10:20 - 10:45
Authentic human cytokines and growth factors for ATMPs from process development through GMP Fiona Bellot, Protein Sales Manager, Proteintech	10:45 - 11:00
The application of light scattering to viral vector analysis; Applications for research, QC and in-line process control Kevin Jackson, Technical Director, Wyatt Technology, UK	11:00 - 11:15
The potential of NKG2D CAR T cells as a therapy for cancer David Gilham, Vice President Research & Development, Celyad	11:15 - 11:50
Cell therapy development for solid tumors - Brought to the next Level by Image Cytometry Martin Theiss, Senior Field Application Scientist, Nexcelom Bioscience	11:50 - 12:20
Networking break	12:20 - 12:20
DOWNSTREAM PROCESSING OF CELL & GENE THERAPIES
An innovative strategy for the production of clinical grade induced pluripotent stem cells Victoria Robertson, Quality Control Manager, RoslinCT, UK	12:40 - 12:55
Pragmatic drug development solutions for virtual and semi-virtual sponsors Nick Meyers, VP Product Development, Boyd Consultants Ltd	12:55 - 13:10
Enabling Autologous CAR T manufacturing at point of care Ohad Karneili, Founder & CEO, Adva Biotechnology	13:10 - 13:35
Closing remarks	13:35 - 13:40
Networking break	13:40 - 14:10
End of Day 1	14:10 - 14:10

Registrations	08:15 - 08:50
Welcome address by MarketsandMarkets	08:50 - 08:55
Opening remarks by Chairperson	08:55 - 09:00
ANALYTICS AND QUALITY CONTROL FOR CELL AND GENE THERAPY PRODUCTS
Starting materials and standards for stem cell-based therapies Elsa Abranches, Acting Head, Division of Advanced Therapies Director, UK Stem Cell Bank	09:00 - 09:30
Engineering characterisation of DASGIP bioreactors towards the optimisation of iPSC-derived Cardiomyocyte differentiation process Andrea Ducci, Associate Professor, UCL Mechanical Engineering	09:25 - 09:50
Analysis of process related impurities in cell & gene therapy products by LC-MS Ejvind Mortz, Chief Operating Officer, Alphalyse	09:50 - 10:20
Extending the shelf life of cell therapy products: No need to freeze Steve Swioklo, CSO and Co-founder, Atelerix Ltd	10:20 - 10:50
To go Viral, or to go Non-Viral, that is the question for cell modification Stefano Baila, Director of Operations & Business Development, Anemocyte	10:50 - 11:15
Networking Break	11:15 - 11:30
Data management and data science tools for accelerating time to market Christoph Herwig, Bioprocess development & facility design, Werum IT Solutions	11:30 - 12:00
LOGISTICS, REGULATORY & INVESTMENT
Raw and starting material control for cell-based medicines Christiane Niederlaender, Regulatory Consultant and Director, AMBR Consulting	12:00 - 12:30
Delving deeper into AAV attributes: Enhanced characterization using multiple technologies John Stenson, Product Manager, Nanomaterials, Malvern Panalytical	12:25 - 12:40
Public sector development of cell and gene therapies Tristan Pritchard-Meaker, , Leiden University Medical Centre	12:40 - 13:05
Unlocking value and investment opportunities in the cell-gene therapy industry	13:05 - 13:30
Closing remarks by Chairperson	13:30 - 13:35
End of Conference	13:35 - 13:35